Latest Miraculins Inc (MCUIF) Headlines
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares") on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent.
Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau:
Miraculins Announces Proposed Ten to One Share Consolidation
Marketwire - Mon Jan 13, 5:30AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that its Board of Directors have approved a consolidation of the Company's common shares ("Common Shares") on the basis of ten pre-consolidation Common Shares for each one post-consolidation Common Share, subject to the approval of the TSX Venture Exchange.
Miraculins Announces Closing of First Tranche of Non-Convertible Secured Loan
Marketwire - Fri Jan 10, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has closed an initial tranche under the non-convertible secured loan with a third party lender (the "Lender") as previously announced on December 23, 2013 (the "Loan"), receiving an advance of CDN$250,000 from the Lender.
Miraculins and Cachet Pharmaceutical Agree to 30-Day Extension on Letter of Intent to Continue Negotiation of Licensing Rights for SCOUT DS(R) Diabetes Test in China
Marketwire - Tue Dec 31, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that the non-binding Letter of Intent (the "LOI") the Company executed with Cachet Pharmaceutical Co. Ltd. ("Cachet") on September 30, 2013, to provide a non-exclusive 90-day negotiation period for Cachet to acquire an exclusive license to commercialize the Company's Scout DS(R) Non-Invasive Diabetes Screening Test in Mainland China, has been extended by mutual agreement of the parties for an additional 30-day period ending January 30, 2014.
Miraculins Files Pre-Submission Documentation with the USFDA for its Scout DS(R) Diabetes Testing Technology
Marketwire - Mon Dec 23, 6:01AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce today that it has filed pre-submission documentation with the USFDA (United States Food and Drug Administration) for its Scout DS(R) System towards securing its ultimate marketing clearance in the United States.
Miraculins Announces Extension of Non-Convertible Secured Loan and Shares for Debt Settlement
Marketwire - Mon Dec 23, 5:46AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has entered into an amending agreement to extend the CDN$1,000,000 non-convertible secured loan (the "Loan") with Gretchen Ross (the "Lender") that was originally announced on October 13, 2011.
Miraculins Announces Non-Convertible Secured Loan of up to $1M CDN
Marketwire - Mon Dec 23, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has arranged a non-convertible secured loan of up to CDN$1,000,000 (the "Loan") with a third party lender, subject to regulatory approval.
Miraculins Announces 2014 Plans for Its Scout DS(R) Non-Invasive Diabetes Screening Technology
Marketwire - Tue Nov 19, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce its plans for the Scout DS(R) non-invasive diabetes screening technology for the upcoming fiscal year, which will include U.S. regulatory activity and expected sales expansion within Canadian pharmacy and employee health screening markets.
Miraculins Announces Final Closing of Private Placement Offering Totalling $1 Million
Marketwire - Fri Nov 01, 5:30AM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the final close of a private placement offering (the "Offering") with gross proceeds to the Company from this second close of $602,000 from the sale of 10,033,333 units ("Units") at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share") and one half of one Share purchase warrant (a "Warrant"). This close brings the total funds raised under the private placement offering initially announced on September 12, 2013 to $1,032,000.
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares") on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent.
Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau:
Miraculins Announces Proposed Ten to One Share Consolidation
Marketwire - Mon Jan 13, 5:30AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that its Board of Directors have approved a consolidation of the Company's common shares ("Common Shares") on the basis of ten pre-consolidation Common Shares for each one post-consolidation Common Share, subject to the approval of the TSX Venture Exchange.
Miraculins Announces Closing of First Tranche of Non-Convertible Secured Loan
Marketwire - Fri Jan 10, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has closed an initial tranche under the non-convertible secured loan with a third party lender (the "Lender") as previously announced on December 23, 2013 (the "Loan"), receiving an advance of CDN$250,000 from the Lender.
Miraculins and Cachet Pharmaceutical Agree to 30-Day Extension on Letter of Intent to Continue Negotiation of Licensing Rights for SCOUT DS(R) Diabetes Test in China
Marketwire - Tue Dec 31, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that the non-binding Letter of Intent (the "LOI") the Company executed with Cachet Pharmaceutical Co. Ltd. ("Cachet") on September 30, 2013, to provide a non-exclusive 90-day negotiation period for Cachet to acquire an exclusive license to commercialize the Company's Scout DS(R) Non-Invasive Diabetes Screening Test in Mainland China, has been extended by mutual agreement of the parties for an additional 30-day period ending January 30, 2014.
Miraculins Files Pre-Submission Documentation with the USFDA for its Scout DS(R) Diabetes Testing Technology
Marketwire - Mon Dec 23, 6:01AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce today that it has filed pre-submission documentation with the USFDA (United States Food and Drug Administration) for its Scout DS(R) System towards securing its ultimate marketing clearance in the United States.
Miraculins Announces Extension of Non-Convertible Secured Loan and Shares for Debt Settlement
Marketwire - Mon Dec 23, 5:46AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has entered into an amending agreement to extend the CDN$1,000,000 non-convertible secured loan (the "Loan") with Gretchen Ross (the "Lender") that was originally announced on October 13, 2011.
Miraculins Announces Non-Convertible Secured Loan of up to $1M CDN
Marketwire - Mon Dec 23, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has arranged a non-convertible secured loan of up to CDN$1,000,000 (the "Loan") with a third party lender, subject to regulatory approval.
Miraculins Announces 2014 Plans for Its Scout DS(R) Non-Invasive Diabetes Screening Technology
Marketwire - Tue Nov 19, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company") a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce its plans for the Scout DS(R) non-invasive diabetes screening technology for the upcoming fiscal year, which will include U.S. regulatory activity and expected sales expansion within Canadian pharmacy and employee health screening markets.
Miraculins Announces Final Closing of Private Placement Offering Totalling $1 Million
Marketwire - Fri Nov 01, 5:30AM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the final close of a private placement offering (the "Offering") with gross proceeds to the Company from this second close of $602,000 from the sale of 10,033,333 units ("Units") at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share") and one half of one Share purchase warrant (a "Warrant"). This close brings the total funds raised under the private placement offering initially announced on September 12, 2013 to $1,032,000.
